Tagged with China

Hong Kong Since first allowing pre-revenue biotechs to list in 2018, the Hong Kong stock exchange has welcomed 59 such companies and is now a leading vehicle for allowing Chinese biopharma to access international capital. Christina Bao, HKEX’s co-head of sales and marketing, discusses listing momentum picking up again after a rocky…

Hong Kong AstraZeneca, the largest overseas pharmaceutical company in mainland China by sales, is also the market leader in Hong Kong and Macau, a territory overseen by General Manager Shan Wu. She outlines the fundamentals behind the company’s success in Greater China, how AstraZeneca is working to bolster Hong Kong’s innovation and…

China A roundup of some of the latest healthcare and pharma news from China including a crackdown on healthcare corruption; AstraZeneca’s cardiovascular mortality drug approval and mRNA manufacturing deal with CanSino; Tigermed’s new Hong Kong HQ; GenScript Biotech/T-Maximum Biotech CAR-T agreement, and the Chinese cabinet’s renewed efforts to encourage foreign biotech…

China First set up in 2014, the Guangdong Medical Valley is an investment incubation platform in southern China focusing on the biomedical and medical device industries. CEO Xia Jiasheng explains how the decision to set up the cluster came about, how it differs from the wealth of other science parks in…

Hong Kong Fresh from the news that one of its AI-designed and discovered drug candidates has entered Phase II human clinical trials – the first time that such a project has made it to that development stage – Insilico Medicine’s Alex Zhavoronkov sat down with PharmaBoardroom to discuss a range of topics.…

Hong Kong The Guangzhou production site of HKEX-listed RNA therapeutics biotech Sirnaomics is overseen by pharma industry veteran Edward Wang. Here, Wang explains his contribution to the development of good manufacturing practices (GMP) in China and why southern China makes sense as a manufacturing location for a local biotech with global ambitions.…

Hong Kong Lawrence Wong outlines how reproductive medicine-focused Ferring Pharmaceuticals is serving the patients of Hong Kong as the city’s birth rates have plateaued, weighs in on why the establishment of a Hong Kong medicines regulator is a strategic imperative, and discusses how his firm is collaborating with colleagues in mainland China…

China Writing in the August edition of DIA’s Global Forum magazine, Wen Yin of the Pfizer China R&D Center and Wanhe Deng of GSK China Investment look back on four years of China’s marketing authorization holder (MAH)-based regulatory system, including the opportunities it presents, and some of the implementation challenges.  …

Hong Kong Dr Brian CHUNG Hon-Yin, Chief Scientific Officer at the Hong Kong Genome Institute (HKGI) and Clinical Associate Professor at the University of Hong Kong (HKU) discusses the creation of the HKGI and the launch of its monumental undertaking, the Hong Kong Genome Project, the first of its kind in the…

Hong Kong Leveraging his 24-year career in Big Pharma, Howard Lin recently moved to set up healthcare and life science consultancy CL Consultancy in Hong Kong. Lin examines the opportunities and challenges for companies in Hong Kong and the Greater Bay Area region today; how the city acts as both a point…

China At a time when the country’s economy has fallen into a slump with the currency sinking to its lowest level in 16 years, Chinese giant Fosun Pharma continues to agressively advance its activities in everything from pharmaceuticals to medical devices and diagnosis to healthcare services. Through its multiple subsidiaries, as…

Hong Kong Looking ahead to the Hong Kong International Biotechnology Convention (BIOHK2023) taking place between 13-16 September 2023 at the Hong Kong Convention and Exhibition Centre, three of the event’s leading lights told PharmaBoardroom about the work that has been done so far to establish Hong Kong as a biotech and innovation…